EPQT – AN ALTERNATIVE TO THE THOROUGH QT TRIAL

Thorough QT trials are often expensive, with an average study costing between $2M and $4M.But, the December 2015 revision to the ICH E14 guidelines has opened the doors to more cost-effective, and less resource intensive solutions to early-phase trials.

Join us in Maidenhead, UK for a half-day workshop on the revised ICH E14 guidelines and the impact the changes have on your early-phase studies.

Participants will interact with industry experts Goran Westerberg, LaCrocina Pharmaceutical Consultants, Raymond Donninger, Covance Clinical Pharmacology Services, and our very own Borje Darpo while they:

  •        Explore the changes in the regulatory landscape
  •        Discuss the benefits of Expert Precision QT (EPQT) modelling in a rare disease setting
  •        Benefit from an overview of Leeds Clinical Research Unit’s data collection capabilities

Unable to attend the workshop?Click here to find out if your study could qualify for a TQT waiver.